Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
EARLY_PHASE1
20 participants
INTERVENTIONAL
2021-11-01
2022-07-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout
NCT05665699
Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/Gout
NCT01129648
D-0120 Safety and PK/PD Study in China
NCT03923868
Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients
NCT05504083
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to Allopurinol
NCT01265264
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
D-0120 plus Allopurinol
D-0120 dosing followed by Allopurinol and combination treatment
D-0120 in combination with Allopurinol
noted above
Allopurinol plus D-0120
Allopurinol dosing followed by D-0120 and combination treatment
D-0120 in combination with Allopurinol
noted above
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
D-0120 in combination with Allopurinol
noted above
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Required evaluation by Investigator for screening and enrollment
* Agreement and compliance with the study and follow-up procedures
Exclusion Criteria
* Pregnant or nursing women
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
InventisBio Co., Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Spaulding Clinical
West Bend, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D0120-104
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.